{
  "schema_version": 1,
  "publication": "cdmos",
  "scope": "Added source-linked answers from this review; vendor statements are not independent tests.",
  "records": [
    {
      "id": "ve-agc-seattle-scope",
      "entity_id": "agc-seattle",
      "field": "protein_biologic_ds_scope",
      "statement": "AGC’s Seattle facility page explicitly identifies GMP mammalian manufacturing and mammalian cell-line development at Seattle.",
      "conditions": "This resolves the earlier network-versus-site gap for broad mammalian scope. Molecule-specific suite fit and open slots still need confirmation.",
      "evidence_role": "vendor_claim",
      "source_url": "https://www.agcbio.com/facilities/seattle",
      "retrieved_at": "2026-11-14T03:58:35.926821+00:00",
      "source_snapshot_sha256": "cd6943eda0c06fc59b7b0e8c8b03f660463507108780e563cf0324cc69ac8608",
      "source_locator": "L143–L153; L182–L185",
      "publisher": "AGC Biologics"
    },
    {
      "id": "ve-agc-seattle-scale",
      "entity_id": "agc-seattle",
      "field": "installed_bioreactor_scale",
      "statement": "AGC lists nine 2,000 L single-use reactors and 3,000 L stainless-steel reactors at Seattle. It describes running multiple 2,000 L vessels together or in sequence.",
      "conditions": "These are equipment and scale-out statements, not one vessel’s working volume or capacity available to book. The number of 3,000 L reactors is not stated.",
      "evidence_role": "vendor_claim",
      "source_url": "https://www.agcbio.com/facilities/seattle",
      "retrieved_at": "2026-11-14T03:58:35.926821+00:00",
      "source_snapshot_sha256": "cd6943eda0c06fc59b7b0e8c8b03f660463507108780e563cf0324cc69ac8608",
      "source_locator": "L182–L199",
      "publisher": "AGC Biologics"
    },
    {
      "id": "ve-fujifilm-mabs",
      "entity_id": "fujifilm-holly-springs",
      "field": "protein_biologic_ds_scope",
      "statement": "Fujifilm’s July 8, 2026 announcement describes Holly Springs as commercial-scale mammalian cell culture manufacturing and says it makes monoclonal antibodies.",
      "conditions": "This is a vendor manufacturing-scope claim. Participation in FDA PreCheck does not establish product approval or a clean inspection.",
      "evidence_role": "vendor_claim",
      "source_url": "https://fujifilmbiotechnologies.fujifilm.com/about/news/fujifilm-biotechnologies-selected-in-fda-precheck-pilot-program-to-advance-u-s-drug-manufacturing/",
      "retrieved_at": "2026-11-14T03:58:35.926821+00:00",
      "source_snapshot_sha256": "a2ed31953752e95898200ea09c6190cad1e45e9f61b4ccd909c7c6cd7d6e8396",
      "source_locator": "L85–L94",
      "publisher": "FUJIFILM Biotechnologies"
    },
    {
      "id": "ve-fujifilm-installed-planned",
      "entity_id": "fujifilm-holly-springs",
      "field": "installed_vs_planned_scale",
      "statement": "Fujifilm reports eight 20,000 L mammalian reactors already opened at Holly Springs. Another eight are under expansion, targeted for late FY2027.",
      "conditions": "The extra reactors are a target, not installed capacity in this comparison. The announced drug-product line is targeted for early 2027. No available slots are published.",
      "evidence_role": "vendor_claim",
      "source_url": "https://fujifilmbiotechnologies.fujifilm.com/about/news/fujifilm-biotechnologies-selected-in-fda-precheck-pilot-program-to-advance-u-s-drug-manufacturing/",
      "retrieved_at": "2026-11-14T03:58:35.926821+00:00",
      "source_snapshot_sha256": "a2ed31953752e95898200ea09c6190cad1e45e9f61b4ccd909c7c6cd7d6e8396",
      "source_locator": "L94–L95",
      "publisher": "FUJIFILM Biotechnologies"
    },
    {
      "id": "ve-avid-development",
      "entity_id": "avid-costa-mesa",
      "field": "protein_biologic_ds_scope",
      "statement": "Avid’s Costa Mesa page documents CHO and HEK293 cell-line development, alongside process, analytical and formulation development for DNA-to-IND programs.",
      "conditions": "Development host capability does not establish the exact host, vessel train or commercial manufacturing scope for your program.",
      "evidence_role": "vendor_claim",
      "source_url": "https://avidbio.com/us-based-cdmo-biologics-facilities/early-phase-costa-mesa/",
      "retrieved_at": "2026-11-14T03:58:35.926821+00:00",
      "source_snapshot_sha256": "a63410c0a6c532d84adcb52dabce7fbd9df12d44dca706829c1bfe85871cc460",
      "source_locator": "L66–L93",
      "publisher": "Avid Bioservices"
    },
    {
      "id": "ve-avid-campus-stage",
      "entity_id": "avid-costa-mesa",
      "field": "clinical_commercial_stage",
      "statement": "Avid identifies Costa Mesa as its early-phase campus and Tustin as the campus for clinical and commercial manufacturing.",
      "conditions": "Do not apply Avid’s commercial company-wide claim to Costa Mesa. The transfer plan and each site’s manufacturing role still need a written proposal.",
      "evidence_role": "vendor_claim",
      "source_url": "https://avidbio.com/about/",
      "retrieved_at": "2026-11-14T03:58:35.926821+00:00",
      "source_snapshot_sha256": "fdcdf2d3284f5ffb11231a0c507892f0305a37ed732ded2d427e6c250674ac35",
      "source_locator": "L104–L115",
      "publisher": "Avid Bioservices"
    }
  ]
}
